乳腺癌新辅助化疗前后对ER、PR、Her-2及Ki-67表达影响与临床意义.pdfVIP

青海大学硕士学位论文 Abstract Abstract Objective: ⑴To investigate the relationship between expressions of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2), Ki-67 antigen (Ki-67) and neoadjuvant chemotherapy in patients with breast cancer 。⑵To study the effect and clinical significance of neoadjuvant chemotherapy on ER,PR,Her-2,Ki-67. Method: Selection of Qinghai university hospital in January 2013 - November 2014, 60 cases accepted after coarse needle biopsy or mammotome minimally invasive rotary cutting the pathology confirmed infiltrating ductal carcinoma of the breast, While new adjuvant chemotherapy and surgery treatment of breast cancer patients, Expressions of ER,PR,Her-2,Ki-67 before and after neoadjuvant chemotherapy were detected by immunohistochemical method. Results: ⑴49 cases (81.7%) reached clinical effective, including 6 cases (10%) of clinical complete remission (cCR),43 cases (71.7%) of clinical partial response (PR). 11 cases (18.3%) were clinical invalid, all of them were stable disease (SD) ,none of progressive disease (PD) and pathologic complete remission (pCR).⑵The clinical efficacy rate of ER( －) patients was 90.5%, which was significantly higher than ER(+++ ～+) patients, 55.6%, the difference was statistically significant (P＜0.05). The clinical efficacy rate of ER( －) patients was 90.5%, which was significantly higher than ER(+++ ～+) patients, 55.6%, the difference was statistically significant (P ＜0.05). The cl